Gujarat Magazine

Postoperative Pain Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Taiwan Liposome Company, Teikoku Pharma, Durect, Pfizer, Vivozon

 Breaking News
  • No posts were found

Postoperative Pain Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Taiwan Liposome Company, Teikoku Pharma, Durect, Pfizer, Vivozon

January 15
08:56 2024
Postoperative Pain Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Taiwan Liposome Company, Teikoku Pharma, Durect, Pfizer, Vivozon
“Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the 7MM.

DelveInsight’s “Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Postoperative Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postoperative Pain Market Forecast

 

Some of the key facts of the Postoperative Pain Market Report: 

  • The Postoperative Pain market size was valued ~USD 2,440 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The number of Postoperative Pain incident cases in the 7MM was 77,984,000 in 2022, and by 2032, that number is predicted to rise
  • Germany had the most incident cases of postoperative pain among the EU4 nations in 2022 (5,046,000 cases), followed by France
  • In Japan, there were 13,335,000 Postoperative Pain event instances in total in 2022, and that number is predicted to rise by 2032
  • According to postoperative pain severity, mild, moderate, and severe cases made up 25%, 45%, and 31%, respectively, of all incident cases in the US in 2022
  • Further division of the visit-specific distribution into inpatient and outpatient categories resulted in 15,200,000 and 1,469,000 cases of postoperative pain in Japan in 2022, respectively
  • According to research done in 2022, mild, moderate, and severe cases of postoperative pain in Germany were found to have severity specific cases of 54%, 27%, and 19%, respectively
  • Key Postoperative Pain Companies: Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
  • Key Postoperative Pain Therapies: TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
  • The Postoperative Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postoperative Pain pipeline products will significantly revolutionize the Postoperative Pain market dynamics.

 

Postoperative Pain Overview

Following surgical treatments, postoperative pain is an expected and brief increase in background pain. It is a kind of pain that normally lasts only a few days to months or pain that is caused by soft tissue damage, such as a paper cut or sprained ankle. The discomfort is brief but eventually goes away as the damaged tissues mend.

 

Get a Free sample for the Postoperative Pain Market Report 

https://www.delveinsight.com/report-store/postoperative-pain-market

 

Postoperative Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Postoperative Pain Epidemiology Segmentation:

The Postoperative Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Postoperative Pain
  • Prevalent Cases of Postoperative Pain by severity
  • Gender-specific Prevalence of Postoperative Pain
  • Diagnosed Cases of Episodic and Chronic Postoperative Pain

 

Download the report to understand which factors are driving Postoperative Pain epidemiology trends @ Postoperative Pain Epidemiology Forecast

 

Postoperative Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Pain market or expected to get launched during the study period. The analysis covers Postoperative Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postoperative Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Postoperative Pain Therapies and Key Companies

  • TLC590: Taiwan Liposome Company (TLC)
  • TPU-006: Teikoku Pharma USA
  • CA-008: Concentric Analgesics
  • SVT-15473: Salvat Laboratories
  • VX-548: Vertex Pharmaceuticals
  • OCS-01: Oculis
  • N1539: Baudax Bio
  • SHR0410: Jiangsu HengRui Medicine
  • Ketorolac tromethamine: Darnitsa Pharma
  • AYX1: Adynxx, Inc.
  • EXPAREL: Pacira Pharma
  • Toragesic®: Apsen Farmaceutica S.A.
  • SABER-Bupivacaine: Durect
  • lyrica: Pfizer
  • VVZ-149: Vivozon, Inc.
  • Tapentadol (OS): Grünenthal GmbH
  • Percocet: Mallinckrodt
  • YM177: Astellas Pharma Inc
  • LMX4: Ferndale Laboratories, Inc.

 

Discover more about therapies set to grab major Postoperative Pain market share @ Postoperative Pain Treatment Market

 

Postoperative Pain Market Strengths

  • Growing research and development and rising awareness about multimodal analgesia among clinicians and patients are increasing the demand for better diagnosis and treatment options for postoperative pain, and drugs in the higher phases of development like APP13007, OCS-01, TLC590, VX-548 are likely to strengthen the overall market
  • Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications

 

Postoperative Pain Market Opportunities

  • Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market
  • Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat postoperative pain
  • Increasing patient population, government findings, and a better research agenda will provide great research and development opportunities

 

Scope of the Postoperative Pain Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Postoperative Pain Companies: Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
  • Key Postoperative Pain Therapies: TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
  • Postoperative Pain Therapeutic Assessment: Postoperative Pain current marketed and Postoperative Pain emerging therapies
  • Postoperative Pain Market Dynamics: Postoperative Pain market drivers and Postoperative Pain market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Postoperative Pain Unmet Needs, KOL’s views, Analyst’s views, Postoperative Pain Market Access and Reimbursement 

 

To know more about Postoperative Pain companies working in the treatment market, visit @ Postoperative Pain Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Postoperative Pain Market Report Introduction

2. Executive Summary for Postoperative Pain

3. SWOT analysis of Postoperative Pain

4. Postoperative Pain Patient Share (%) Overview at a Glance

5. Postoperative Pain Market Overview at a Glance

6. Postoperative Pain Disease Background and Overview

7. Postoperative Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Postoperative Pain 

9. Postoperative Pain Current Treatment and Medical Practices

10. Postoperative Pain Unmet Needs

11. Postoperative Pain Emerging Therapies

12. Postoperative Pain Market Outlook

13. Country-Wise Postoperative Pain Market Analysis (2019–2032)

14. Postoperative Pain Market Access and Reimbursement of Therapies

15. Postoperative Pain Market Drivers

16. Postoperative Pain Market Barriers

17.  Postoperative Pain Appendix

18. Postoperative Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services